Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nanoform Finland

0.88 EUR

-2.11 %

3,688 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

-2.11 %
-23.22 %
-24.66 %
-23.08 %
-14.27 %
-28.21 %
-69.60 %
-87.70 %
-82.51 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
75.65M EUR
Turnover
196.05K EUR
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2.
2026

Annual report '25

14.4.
2026

General meeting '26

19.5.
2026

Interim report Q1'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
cash.ch Kursraketen im Depot: Diese fünf Biotech-Titel könnten sich verdreifachen Biotechnologie ist wieder «en vogue». Diese Titel haben allesamt mehr als 200 Prozent Kurspotenzial. Nano mentioned on a Swiss investment site. “Those who are not afraid of the risk associated with ...
1/23/2026, 11:40 AM
by Latupuikko
16
Today I stepped aside from this holding, moving to the sidelines to watch. I started feeling more and more anxious about the excessive dependence on the nanoenzalutamide project to replenish the cash reserves over the next couple of years. Over the last couple of years, some flags...
1/29/2026, 7:47 PM
by JusaVaan
11
Nanoform.pdf (8.9 MB) nanoform.com AI-Transcript-Nanoform-Capital-Markets-Day-December-16th-2025-Helsinki.pdf 454.46 KB Anyone else interested should also check out the CMD day agenda. Unfortunately, the Q&A is not included. Interesting stuff. Peter Hänninen: "This is a slide (87...
yesterday
by Latupuikko
10
True, that’s how it was—the results were provided in connection with the earnings report. Perhaps it is possible that the results are already known but won’t be published until the Q4 report. However, I find that a bit strange from both a regulatory and company communication perspective...
yesterday
by Zeta
8
This subcutaneous formulation of biologics really has remarkable potential. I haven’t read the CMD transcripts yet, but I did flip through the slides earlier. There seem to be limited competitors regarding this technology at the moment. These slides from the CMD show those who have...
yesterday
by jerej
8
The Trump administration is starting to negotiate drug price reductions again. Now there are 15 drugs on the list, including Erleada (apalutamide). Apalutamide is one candidate for nanoformulated drugs, in addition to enzalutamide. cms.gov CMS Announces Selection of Drugs for Third...
1/28/2026, 1:29 PM
by jerej
6
In my own mind, I have also been wrestling with bullish and bearish views on these future potentials that, if successful, could multiply the value of the investment many times over in a few years—and on the other hand, the risk that if the nanoenzalutamide launch is delayed or doesn...
yesterday
by JusaVaan
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.